| Literature DB >> 34729030 |
Mayakrishnan Vijayakumar1, Balakarthikeyan Janani2, Priya Kannappan2, Senthil Renganathan3,4, Sameer Al-Ghamdi5, Mohammed Alsaidan6, Mohamed A Abdelaziz7,8, Abubucker Peer Mohideen7, Mohammad Shahid7, Thiyagarajan Ramesh7.
Abstract
BACKGROUND: The ongoing global outbreak of new corona virus (SARS-CoV-2) has been recognized as global public health concern since it causes high morbidity and mortality every day. Due to the rapid spreading and re-emerging, we need to find a potent drug against SARS-CoV-2. Synthetic drugs, such as hydroxychloroquine, remdisivir have paid more attention and the effects of these drugs are still under investigation, due to their severe side effects. Therefore, the aim of the present study was performed to identify the potential inhibitor against main protease SARS-CoV-2 6LU7.Entities:
Keywords: ACE 2, Angiotensin Converting Enzyme; Andrographolide; CNS, central nervous system; COVID-19 (6LU7); COVID-19, coronavirus disease 2019; Corona; Diterpenoids; Molecular dynamic simulations; Mpro, Main protease; Natural compounds; SARS-CoV-2; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2
Year: 2021 PMID: 34729030 PMCID: PMC8555113 DOI: 10.1016/j.sjbs.2021.10.060
Source DB: PubMed Journal: Saudi J Biol Sci ISSN: 2213-7106 Impact factor: 4.219
List of selected bioactive compounds from A. panniculata for potential antiviral activity against Mpro of COVID-19.
| N3 | C35H48N6O8 | – | |
| Andrographolide | C20H30O5 | Anticancer, anti-diabetic, anti-inflammatory, antibacterial, anti-malarial, anti-hepatitis, anti-HIV, anti-atherosclerosis and hepatoprotective | |
| Andrograpanin | C20H30O3 | Anti-biofilm, anti-HIV, | |
| Neoandrographolide | C26H40O8 | Anti-inflammatory, anti-malarial, immunomodulatory | |
| 14-Deoxyandrographolide | C20H30O4 | Anticancer, anti-inflammatory, anti-HIV | |
| 14-deoxy-11,12-didehydroandropholide | C20H28O4 | Anti-cancer, anti-HIV, anti-atherosclerosis, relaxant, anti-hyperglycemic |
Lipinski’s rule of five (RO5) of Mpro of COVID-19 and selected bioactive compounds from A. panniculata for protein potential inhibitors.
| N3 | C35H48N6O8 | 680.00 | 0.6967 | 5 | 12 | + | – |
| Andrographolide | C20H30O5 | 332.00 | 3.1153 | 2 | 4 | – | + |
| Andrograpanin | C20H30O3 | 318.00 | 4.0209 | 1 | 3 | – | + |
| Neoandrographolide | C26H40O8 | 480.00 | 1.8452 | 4 | 8 | – | + |
| 14-Deoxyandrographolide | C20H30O4 | 334.00 | 2.9917 | 2 | 4 | – | + |
| 14-deoxy-11,12-didehydroandropholide | C20H28O4 | 332.00 | 2.7677 | 2 | 4 | – | + |
Pharmacokinetics, absorption, distribution, excretion and toxicity of selected bioactive compounds from A. panniculata determined by using SWISS ADME and pkCSM ADMET web server.
| PSA | 197.83 | 86.99 | 46.53 | 125.68 | 66.76 | 66.76 |
| AlogP98 | 2.74 | 2.33 | 3.95 | 2.33 | 3.15 | 2.52 |
| Water solubility | −4.181 | −3.384 | −4.199 | −3.826 | −3.296 | −3.203 |
| CaCo2 permeability | 0.501 | 1.24 | 1.444 | 0.502 | 1.236 | 1.253 |
| Intestinal absorption | 63.398 | 98.427 | 100 | 49.295 | 98.713 | 99.561 |
| Skin permeability | −2.736 | −3.119 | −3.13 | −2.747 | −3.106 | −3.117 |
| P-glycoprotein substrate | + | + | + | + | + | + |
| P-glycoprotein-I inhibitor | + | + | + | + | + | + |
| P-glycoprotein-II inhibitor | – | – | – | – | – | – |
| VDss (human) | −0.764 | −0.268 | −0.025 | −0.819 | −0.252 | −0.259 |
| Fraction unbound | 0.052 | 0.149 | 0.015 | 0.202 | 0.158 | 0.175 |
| BBB permeability | −1.725 | 0.046 | −0.158 | −1.165 | 0.017 | 0.013 |
| CNS permeability | −4.013 | −2.083 | −1.483 | −2.876 | −2.208 | −2.286 |
| CYP2D6 substrate | – | – | – | – | – | – |
| CYP3A4 substrate | + | + | + | – | + | + |
| CYP1A2 inhibitor | – | – | – | – | – | – |
| CYP2C19 inhibitor | – | – | – | – | – | – |
| CYP2C9 inhibitor | – | – | – | – | – | – |
| CYP2D6 inhibitor | – | – | – | – | – | – |
| CYP3A4 inhibitor | + | – | – | – | – | – |
| Total clearance | 0.713 | 1.19 | 1.115 | 0.952 | 1.175 | 1.301 |
| Renal OCT2 substrate | – | + | – | – | + | + |
| AMES toxicity | – | – | – | – | – | – |
| Maximum tolerated dose | 0.015 | −0.124 | −0.616 | −0.953 | −0.127 | −0.127 |
| hERG I inhibitor | – | – | – | – | – | – |
| hERG II inhibitor | + | – | – | – | – | – |
| Oral rate acute toxicity (LD50) | 4.138 | 3.433 | 2.678 | 4.065 | 2.655 | 2.622 |
| Oral rat chronic toxicity (LOAEL) | 3.606 | 1.57 | 2.056 | 3.566 | 1.567 | 1.487 |
| Hepatotoxicity | + | – | – | – | – | – |
| Skin sensitization | – | – | – | – | – | – |
| 0.285 | 0.443 | 0.865 | 0.285 | 0.447 | 0.441 | |
| Minnow toxicity | 4.885 | 0.484 | −0.723 | 5.135 | 0.443 | 0.537 |
Molecular docking results with maximum binding affinity of selected bioactive compounds from A. panniculata against Mpro COVID-19 (6LU7) and its cellular receptor.
| N3 | C35H48N6O8 | 680.00 | 4 | 1.56, 2.50, 3.07, 2.58 | −7.69 | 2.32 | Gly143, Ser144, His164, Glu166 |
| Andrographolide | C20H30O5 | 332.00 | 2 | 2.07, 1.90 | −8.09 | 1.18 | Phe140, Ser144 |
| Andrograpanin | C20H30O3 | 318.00 | 2 | 2.94, 2.13 | −7.62 | 2.59 | His41, Asn142 |
| Neoandrographolide | C26H40O8 | 480.00 | 6 | 2.62, 2.74, 2.17, 1.96, 2.07, 2.20 | −7.76 | 2.05 | Cys145, Met165, Glu166, Arg188, Gln189 |
| 14-Deoxyandrographolide | C20H30O4 | 334.00 | 3 | 2.99, 2.00, 2.17 | −7.67 | 2.40 | His41, Leu141 |
| 14-deoxy-11,12-didehydroandropholide | C20H28O4 | 332.00 | 4 | 2.82, 2.09, 1.98, 2.25 | −7.92 | 1.57 | His41, Tyr54, Leu141, Ser144 |
Fig. 1(a) Binding sites for N3 ligands within Mpro of COVID-19. (b) Binding sites for andrographolide ligands within Mpro of COVID-19. (c) Binding sites for andrograpanin ligands within Mpro of COVID-19. (d) Binding sites for neoandrographolide ligands within Mpro of COVID-19. (e) Binding sites for 14-deoxyandrographolide ligands within Mpro of COVID-19. . (f) Binding sites for 14–11,12-didehydroandrographolide ligands within Mpro of COVID-19.
Fig. 2(a and b) 2D and 3D structural interaction view of N3 ligands with Mpro of COVID-19. (c and d) 2D and 3D structural interaction view of andrographolide ligands with Mpro of COVID-19. (e and f) 2D and 3D structural interaction view of neoandrographolide ligands with Mpro of COVID-19.
Fig. 3(a and b) 2D and 3D structural interaction view of andrograpanin ligands with Mpro of COVID-19. (c and d) 2D and 3D structural interaction view of 14-deoxyandrographolide ligands with Mpro of COVID-19. (e and f) 2D and 3D structural interaction view of 14–11,12-didehydroandrographolide ligands with Mpro of COVID-19.
Fig. 4The RMSD plots, (a) andrographolide, (b) andrographonin, (c) neoandrographolide, (d) 14-deoxyandrographolide, (e) 14-deoxy-11,12-didehydroandropholide, are clearly indicating the back bone and ligand fit following the stability curve and the ligands found constantly (block line: protein C-α and red line: ligand rmsd).
Fig. 5(a) Ligand fit RMSD comparison among diterpenoids exhibits atomic details of aberration. (b) Predicted free energy of binding of diterpenoids reveals the interaction energy. (c) XY-scatter diagram of root mean square fluctuation indicating the amino acids fluctuation with residue number.
Fig. 6The hydrogen bond plots, (a) andrographolide, (b) andrographonin, (c) neoandrographolide, (d) 14-deoxyandrographolide, (e) 14-deoxy-11,12-didehydroandropholide, are dictating the movements and number of hydrogen bonds with 50,000 picoseconds (ps).